The velocity of flowing blood in vessels decreases progressively from the center to the wall and the relative motion between adjacent layers of fluid creates a shearing effect that, inversely to velocity, is greatest at the wall and decreases towards the center (supplementary Figure 1) . Shear rate is the difference in flow velocity as a function of distance from the wall and is expressed in cm/s per cm or the equivalent inverse second (s -1 ). Shear stress is the resulting force per unit area and is expressed in pascal (Pa), equivalent to one newton/m 2 (N/m 2 ), or in dyne/cm 2 (1 Pa = 10 dyne/cm 2 ). Shear rate is directly proportional to shear stress and inversely proportional to dynamic fluid viscosity, which is expressed in Pa⋅s or dyne/cm 2 ⋅s, the latter equivalent to poise (P; 1 P = 0.1 Pa⋅s). In blood, the viscosity of which is ~ 3-4 millipascal (mPa)⋅s or 3-4 centipoise (cP), a shear rate of 25 s -1 causes a shear stress of ~ 1 dyne/cm 2 (0.1 Pa). The highest wall shear rate in the normal human circulation, estimated to vary between 500 and 5,000 s -1 (corresponding to a shear stress of ~ 20-200 dyne/cm 2 ), occurs in small arterioles of 10-50 µm diameter.
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Function of endogenous matrix VWF and immobilized plasma-derived VWF
The relative contribution of these two forms of VWF to platelet adhesion was elucidated by studies on the transplant of normal pig bone marrow into pigs affected by severe von Willebrand disease, characterized by a complete deficiency of VWF. 2 As expected, the procedure could not correct the endothelial cell defect, thus there continued to be no VWF secretion into blood or subendothelial matrix while the VWF content in platelet α-granules was normalized. This was not sufficient to restore a normal hemostasis, although some transplanted animals showed a partial amelioration of the prolonged bleeding time. The latter finding is in agreement with the concept that α-granule-derived VWF, released after activation, can contribute to thrombus growth 3 but not to the initial platelet adhesion occurring before activation. 4 In contrast, hemostasis was completely normal in the transplanted pigs after infusion of normal plasma VWF. 2 The prolonged bleeding time of pigs with severe von Willebrand disease was also normalized by transfusion of VWF concentrates alone, 5 even though their platelet VWF remained absent, however a considerably higher dose was required than in transplanted pigs with normal platelet VWF. 2 These results prove that plasma VWF can initiate platelet adhesion after binding to the vessel wall in the absence of matrix VWF, and supports subsequent thrombus growth with the contribution of platelet-released VWF that, however, is not essential.
The interaction of VWF with extracellular matrix components
The VWF A1 domain (VWF-A1), comprising residues 497-716 of the mature subunit (add 763
to obtain the corresponding residue number in pre-pro-VWF), 6 was initially shown to interact with collagen types I 7;8 and III, 9 but its main role may be binding to collagen type VI. 10;11 The latter contains VWF type A domains in its non-collagenous regions that may become engaged in homotypic interactions with VWF-A1. 11;12 The VWF A3 domain (VWF-A3), comprising residues 910-1111, also binds to collagen types I and III, 8;9;13 and is apparently necessary and sufficient to mediate the interaction with fibrillar collagens. 14;15 The VWF-A3 residues involved in collagen binding have been mapped, 16 ;17 and a high affinity binding site for VWF has been identified in collagen type III. 18 Fluid dynamic conditions and mechanical forces may modulate the VWF-collagen interaction, and the interplay of domains A1 and A3 may be necessary to support VWF immobilization onto extracellular matrices containing various collagen types. 11 Of note, VWF multimer size directly correlates with the affinity for collagen binding. showing that ADAMTS-13 can further cleave circulating VWF multimers while they mediate activation-independent interplatelet cohesion induced by elevated shear stress, resulting in a time-dependent dispersion of the aggregates. 48 In contrast, the protease appeared to have no effect, at least under the ex vivo conditions studied, when thrombus formation was induced by blood exposure to a collagen surface.
The latter finding stands in apparent contradiction with the results of in vivo studies in mouse thrombosis models, which have shown the ability of recombinant ADAMTS-13 to dissolve experimentally-induced thrombi in the arteriolar circulation leading to the conclusion that the protease could be used as an antithrombotic agent. 49 While the effect of ADAMTS-13 on microarteriolar thrombi is in agreement with the phenotype caused by its deficiency, i.e. microarteriolar thrombosis, 47 the situation may be different in larger arteries. In this case, the anti-thrombotic activity of ADAMTS-13 may depend on the extent to which adhesive molecules such as fibrinogen and fibronectin, rather than VWF, contribute to platelet aggregation. Thus, the anti-thrombotic activity of ADAMTS-13 may be selective for platelet aggregation under high shear stress conditions in which VWF is important for platelet cohesion. develop. In this regard, it is intriguing to observe that a recent study found a positive correlation between ADAMTS-13 levels and the risk of myocardial infarction in men, 51 a finding that is in apparent contrast with the suggestion that ADAMTS-13 may act as an anti-thrombotic agent.
The mechanism through which increased ADAMTS-13 levels and/or activity might constitute a risk for arterial thrombosis remains to be understood.
Activation of adherent platelets
Outside-in signaling required for platelet activation is linked to the engagement of the primary adhesion receptors for both VWF (GP Ibα) and collagen (GP VI and the integrin α2β1 Activation through GP Ibα. VWF binding to GP Ibα supports platelet tethering to thrombogenic substrates, but the extent to which it contributes to subsequent activation is less well defined. 54 In fact, VWF in the vessel wall is associated with other potent platelet agonists, such as collagen, and it is difficult to ascertain whether VWF-induced GP Ibα signaling adds significantly to the overall activation response following initial adhesion. One problem is that, to date, it has not been possible to separate the adhesive and signaling functions of the receptor as the latter is dependent on the former, which in turn is essential for the initial tethering that precedes any other response when shear rates are elevated. It seems reasonable to assume that, if to activation of phospholipase C-γ2 (PLC-γ2) and subsequent formation of inositol triphosphate (leading to Ca 2+ mobilization) and diacylglycerol (leading to activation of protein kinase C).
57;62
It has been shown, however, that mouse platelets lacking FcR-γ undergo only slightly lower than normal Ca 2+ oscillations after adhering to dimeric VWF-A1, suggesting that FcR-γ may contribute to but is not essential for activation induced by GP Ibα. Signals elicited by platelet adhesion to VWF-A1 under flow can activate αIIbβ3 independently of other receptors, 63 with the contribution of the adaptor molecule, ADAP, for optimal efficiency. 64 The cytoplasmic tail of GP Ibα is associated with actin binding protein and 14-3-3ζ, [65] [66] [67] which are linked to several intracellular signaling molecules including phosphatidylinositol (PI) 3-kinase, focal adhesion kinase, Src-related tyrosine kinases (Syk, Src, Fyn Lyn and Yes), GTPaseactivating protein, and tyrosine phosphatases (PTP-1B and SHPTP10). 68 Thus, 14-3-3ζ may be a relevant modulator of signaling through GP Ib-IX-V. [69] [70] [71] Moreover, a membrane-permeable Figure 3) . PI3-kinase inhibition or ADP removal by apyrase block γ peaks and prevent platelet aggregation. 55;75;76 This ADP-dependent reinforcement of platelet activation is mediated by the P2Y 12 receptor. 74 Only a small proportion of platelets translocating on immobilized VWF exhibit type γ Ca 2+ peaks, 55;74 suggesting that a synergy between this and other activation pathways is necessary for platelet activation following adhesion. Such a functional arrangement may be important in the modulation of initial thrombus formation.
GP Ibα is the major α-thrombin binding site on the platelet surface, accounting for as much as 90% of the total protease bound. 77 The functional significance of this interaction is still debated, in spite of the fact that α-thrombin binding to GP Ibα induces platelet adhesion, spreading, dense granule secretion, and aggregation. 78;79 Among the suggested possibilities is a role of GP Ibα in positioning α-thrombin for optimal cleavage of the protease-activated receptors, PAR-1 and PAR-4, 80-82 which would then be responsible for the signaling. 83 Crystallographic studies have shown the potential for GP Ibα to bind two separate thrombin molecules by interacting with both exosite I and II of the protease. 84;85 Such a mode of interaction may promote receptor crosslinking and aid in platelet activation. GP V, which is closely associated with GP Ib-IX, is a substrate for proteolysis by α-thrombin, 86 and the possible functional significance of its cleavage has emerged from the study of genetically modified mice. 87 The platelets of GP V -/-mice -which are normal in size, express normal amounts of the modified GP Ib-IX complex, and display normal function with regard to VWF binding -exhibit an enhanced response to thrombin. 87 The finding has been explained by the observation that GP V -/-platelets, but not those of wild type mice, are activated by proteolytically inactive thrombin, 88 which cannot cleave the PARs but binds to GP Ib-IX with equal affinity as α-thrombin. In contrast, proteolytically inactive thrombin could stimulate wild type platelets only if they had been pre-treated with a low dose of α-thrombin, sufficient to cleave GP V but not to activate through the PARs. 88 The conclusion based on these results is that α-thrombin can initiate platelet signaling upon interacting with GP Ibα independently of proteolytic activity, but proteolysis is required to release the inhibitory effect that GP V in the GP Ib-IX-V receptor complex displays on this signaling pathway.
Platelet activating signals transmitted through GP Ibα appear to involve cGMP-dependent protein kinase (PKG), a conclusion proposed by a group of investigators who found that PKG knockout mice exhibit impaired platelet responses to VWF or low doses of α-thrombin associated with a prolongation of the bleeding time. Moreover, the aggregation of human platelets induced by VWF or low concentrations of α-thrombin was diminished in the presence of PKG inhibitors and increased by cGMP or by the cGMP-enhancing agent, sildenafil. 89 Evidence has been presented that this activation pathway involves p38, a mitogen-activated protein kinase (MAPK), which in turn mediates the PKG-dependent phosphorylation of extracellular stimuli-responsive kinase (ERK). 90 These findings are still considered controversial by some investigators, as they are in contrast to the currently accepted paradigm that PKG inhibits platelet activation. 91;92 A potential confounding factor is that cGMP-dependent platelet responses following GP Ibα ligation appear to be biphasic, with an initial transient stimulation that promotes platelet aggregation rapidly followed by an inhibitory state that limits the size of aggregates. 89 The concept of an initial platelet stimulation mediated by PKG and induced by cGMP elevation has been expanded to include signaling pathways involving Gq-and Gi-coupled agonist receptors. 93 A related and equally unexpected finding has been that nitric oxide (NO), also generally considered a potent inhibitor of platelet activation, 91;92 appears to act as a key messenger in PKG-dependent platelet activation.
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Activation through the collagen receptors. The two major collagen receptors on the platelet surface, α2β1 and GP VI, have both been implicated in generating signals that lead to platelet activation, although some investigators have concluded that GP VI plays the central if not exclusive role in the interaction with collagen. 95;96 Like other integrins, α2β1 requires the transition from an "inactive" to an "active" state in order to bind to its ligand with high affinity, thus its function may be viewed as downstream of initial activating signals that proceed from the GP VI-collagen interaction 97 or other stimuli. In this regard, evidence has been presented that activation of another integrin, αIIbβ3, is not only sufficient but also absolutely required for α2β1 activation on platelets. 98 In any case, several experimental results indicate that α2β1 is a signaling receptor and contributes to collagen-mediated platelet responses. [99] [100] [101] [102] [103] For example, antibodies and other reagents directed against α2β1 inhibit platelet activation and aggregation induced by collagen, but the effect can be overcome with increasing concentrations of the agonist. 104 Similarly, the snake venom jararhagin, which cleaves the α2 subunit inactivating the integrin, inhibits collagen-dependent phosphorylation of Syk and other proteins at low but not high agonist concentrations. These findings support the conclusion that α2β1 may contribute to but is not essential for collagen-dependent platelet functions.
GP VI plays a major role in collagen-induced platelet activation, 95 Figure 2) . 120 Both ADP receptors, P2Y 1 and P2Y 12 , are involved in the process, which can be demonstrated experimentally by two-stage perfusion experiments in which normal blood is first exposed to a thrombogenic surface, such as collagen type I fibers, followed by blood containing specific inhibitors. In such a manner, it has been shown that a thrombus can begin to disperse even after several minutes of growth if ADP activation pathways are blocked, intracytoplasmic Ca 2+ elevations are prevented or inhibitors of αIIbβ3 function are added. 121 These findings indicate that platelet activation must be sustained in order to keep adhesive ligands bound to αIIbβ3 in a stable manner. It should be considered, however, that ex vivo experiments might overemphasize platelet-dependent mechanisms of this kind because anticoagulants used to handle blood outside of vessels markedly suppress α-thrombin generation and/or activity and reduce the deposition of fibrin that normally contributes to thrombus stability.
Nevertheless, sustained platelet activation may be critical for maintaining the integrity of platelet aggregates, particularly in rapid arterial flow conditions and in the early stages of thrombus development.
Adhesive molecules bound to or expressed onto the membrane of activated platelet are crucial for the rapid growth of stable thrombi. One example of this function is the role that fibrinogen (likely after conversion to fibrin) plays in anchoring aggregated platelets to the site of vascular injury, thus preventing downstream embolization under the effects of flow. 122 Several specific interactions have been identified that directly enhance the cohesion between platelets initially established through well-known adhesive ligands (VWF, fibrinogen, fibronectin) and receptors (GP Ibα and αIIbβ3). Two main mechanisms can be envisioned to operate in this regard, one resulting in the generation of signals that enhance or sustain platelet activation, and the other based on homophilic or heterophilic interactions that add adhesive strength to platelet aggregates. The hormone leptin is an example of the first type of action, as it may reinforce the response of platelets to weak agonist stimulation thus contributing to the stability of platelet aggregation. 123 The effect of leptin on thrombus growth has been confirmed with in vivo experiments in obese mice, who lack leptin and exhibit delayed thrombotic occlusion with frequent embolization in injured arteries. 124 Moreover, inhibition of endogenous leptin has been found to protect mice from arterial and venous thrombosis. 125 In human obesity, therefore, in which leptin resistance leads to high circulating levels of the hormone, 125 the effect of leptin on platelet activation may represent an additional prothrombotic factor.
Cellular pathways involved in inflammatory and immune responses also appear to have prothrombotic effects. CD40 ligand (CD40L), a member of the tumor necrosis factor family of ligands, has been detected on the surface of activated platelets where it interacts with αIIbβ3 through an integrin recognition sequence (KGD). In the absence of CD40L, platelet aggregates formed in experimental in vivo models of thrombosis are unstable, confirming the ability of this protein to support platelet-platelet cohesion under high shear stress conditions via an αIIbβ3-dependent mechanism.
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Growth arrest-specific gene 6 product (Gas6) is a vitamin K-dependent protein homologous to the anticoagulant cofactor, protein S, whose absence or inactivation was reported to protect mice from fatal thromboembolism. 127 Gas6 is present in plasma and in the α-granules of mouse platelets, from which it is secreted upon activation, but may be absent in human platelets. 128 Because of the latter observation, the relevance of Gas6 in human platelet physiology is being reevaluated as it may depend on the function of the plasma-derived protein only. On the other hand, all three known Gas6 receptors (Axl, Sky, and Mer) are present on mouse and human platelets, and their inactivation or stimulation results in the expected inhibition or enhancement of agonist-induced platelet activation responses. 129 Thus, Gas6-dependent pathways may represent an amplification mechanism for platelet aggregate stability.
Eph kinases and ephrins are families of membrane bound molecules that interact with each other, exhibiting a major role in neuronal organization and as early markers for vascular commitment to arterial or venous development. Platelet-expressed Eph/ephrins include EphA4 and ephrinB1, which appear to contribute to "outside-in" signals originating from ligandoccupied αIIbβ3. Inhibition of Eph/ephrin interactions results in a diminution of the volume of thrombi formed on a collagen type I surface, presumably as a consequence of decreased aggregate cohesion. 130 A strategy has been proposed to identify molecules that are phosphorylated following the induction of platelet aggregation, as this could indicate a specific role in controlling thrombus stability. 131 Two studies have recently verified the validity of this hypothesis. In one, a novel membrane protein has been identified, platelet endothelial aggregation receptor 1 (PEAR1), that appears to signal secondary to αIIbβ3-mediated platelet-platelet contacts. 131 Future studies will indicate the pathophysiological significance of this finding. In another study, evidence has been presented for the prothrombotic function of CD84 and SLAM (signaling lymphocyte activation molecule), both members of the same family of homophilic adhesion receptors. Immobilized CD84 can promote platelet microaggregation, and SLAM -/-mice exhibit decreased agonistinduced platelet aggregation, a defect confirmed by intravital studies of thrombus formation in injured vessels. 132 Because numerous cell signaling and adhesive pathways potentially involved in controlling platelet thrombus integrity have already been identified, an obvious challenge for the future will be the integration of this analytical knowledge into a comprehensive representation of the mechanisms of platelet response to vascular injury.
Platelet adhesion in inflammation, atherogenesis and host defense mechanisms
As sentinels of vascular integrity, platelets may be responsible for orchestrating the localization released molecules such as P-selectin 133 and VWF. 134 Once interacting with the endothelial surface, or subendothelial structures in case of a more severe damage, platelets may produce a varied response modulated by the nature and extent of the vessel wall perturbation, and thus selectively attract different types of leukocytes that, in turn, mediate specific defense mechanisms. In this regard, for example, it has been shown that granulocytes roll and adhere onto activated platelets, and eventually transmigrate through the vessel wall, via a dual process mediated by P-selectin and β2 integrin ligands. 135 Platelet and leukocyte adhesive interactions, therefore, may elicit reciprocal influences in the course of inflammatory, atherogenic and thrombotic processes. process related to but distinct from the peripheral targeting of antigen-specific CD8 + cytotoxic Tlymphocytes. The ability of platelets to promote the site-specific localization of leukocytes through selective adhesive interactions may be the paradigm of processes that involve other cell types and may be relevant in angiogenesis 140 and tumor metastasis.
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The study of platelet adhesive functions by intravital microscopy Studying the mechanisms of thrombus formation in the vasculature of a living animal, typically performed with videomicroscopy techniques, provides a global view of the process, with the contribution of all pro-and anti-thrombotic factors 143 responding to lesions of endothelial and subendothelial structures. 133;144 Moreover, intravital experiments avoid the problem of using anticoagulants, as required for the ex vivo perfusion of blood specimens through flow chambers.
One can thus monitor concurrently the aggregation of platelets and deposition of fibrin, 145 and derive quantitative information that is temporally and spatially relevant to explain the process of thrombus formation, in particular with respect to the events that initiate and consolidate the response to vascular injury. For example, intravital thrombosis models are providing a new perspective on the role of tissue factor, 146;147 and have revealed the unexpected importance of coagulation factor XII in the formation of platelet thrombi. Factor XII (Hageman factor) contributes to the initiation of the contact phase of coagulation, which induces clotting on negatively charged surfaces but may be less crucial to secure normal hemostasis in vivo. In fact, factor XII deficiency in humans is not associated with a bleeding phenotype, and affected patients have no apparent defect of coagulation or platelet function. It was, therefore, surprising to observe that mice with ablation of the factor XII gene exhibit a markedly decreased platelet response in an experimental model of arterial thrombosis, 148 a finding reinforced by the observation that these mice are protected from pathological thrombosis caused by cerebral ischemia. 149 The mechanism through which factor XII contributes to thrombus formation is not yet fully elucidated, but the relevance of its role is likely to be inversely related to the levels of exposed tissue factor, considered the main trigger of coagulation, which in turn may depend on the nature of the vascular lesion. Another important aspect of in vivo thrombosis models is to provide information on the mechanisms relevant to the stability of platelet aggregates, which may be essential for the development of occluding arterial thrombi. Studies of this kind, for example, have shown that plasminogen activator inhibitor-1 and its cofactor, vitronectin, are required for the integrity of thrombi that develop in response to vascular injury. 150 In spite of the obvious relevance of the results provided by thrombosis model studied by intravital microscopy, it should be considered that no experimental method is without limitations, and conclusions from live animal experiments may not be directly applicable to human pathological conditions. This is particularly true with respect to vascular diseases, because experimental lesions in healthy vessels most likely elicit different thrombogenic responses as compared to those occurring in arteries altered by chronic degenerative processes such as atherosclerosis. In fact, experimental evidence indicates that intravital models of thrombosis are greatly influenced by the methods used to cause injury and the target vessel used, which may explain the variability of reported results. 151 Understanding the mechanisms that modulate a thrombogenic response in relation to the nature of the initiating vascular lesion remains a challenge for both ex vivo and in vivo experimentation. 
